December 27, 2021
Eisai said on December 24 that its anti-amyloid beta (Aβ) protofibril antibody lecanemab being jointly developed with Biogen for early Alzheimer’s disease has earned Fast Track designation from the US FDA. The drug had been granted the Breakthrough Therapy tag...read more